Skin cancer patients with few options gain a better-tolerated treatment. Sun Pharma's immunotherapy UNLOXCYT has been upgraded to a 'preferred' Category 2A option in the influential US NCCN cancer guidelines for advanced cutaneous squamous cell carcinoma. In trials more than half of patients responded, with low rates of serious side effects. The guideline backing can ease insurance coverage and widen patient access, while strengthening global sales for India's largest drugmaker.